Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirzepatide - Eli Lilly and Company

Drug Profile

Tirzepatide - Eli Lilly and Company

Alternative Names: GIP/GLP-1 RA; LY-3298176; Mounjaro; Zepbound

Latest Information Update: 09 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperglycaemics; Glucagon-like peptides; Heart failure therapies; Hepatoprotectants; Obesity therapies
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Phase III Cardiovascular disorders; Heart failure; Sleep apnoea syndrome
  • Phase II Kidney disorders; Non-alcoholic steatohepatitis

Most Recent Events

  • 06 Feb 2024 Efficacy data from the phase II SYNERGY-NASH trial in Non-alcoholic steatohepatitis released by Eli Lilly and Company
  • 12 Dec 2023 Updated efficacy and adverse events data from a phase III SURMOUNT-4 trial in Obesity released by Eli Lilly and Company
  • 05 Dec 2023 Launched for Obesity in USA (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top